Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration
September 06, 2022 08:05 ET
|
Spero Therapeutics, Inc.
Alignment with the FDA on a regulatory path forward for the continued development of tebipenem Hbr FDA feedback indicates positive results from a single additional Phase 3 clinical trial in patients...
Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update
August 10, 2022 16:05 ET
|
Spero Therapeutics, Inc.
Initiation of a Placebo-controlled Phase 2 Trial of SPR720 in Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Expected in 4Q 2022 Initiation of a Phase 2 Cross-indication Resistant Pathogen...
Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
August 09, 2022 08:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Wednesday, August 10, 2022...
Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application
June 27, 2022 16:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug...
Spero Therapeutics Announces First Quarter 2022 Operating Results and Provides Business Update
May 16, 2022 16:05 ET
|
Spero Therapeutics, Inc.
New Strategic Direction Focuses on Advancing the Clinical Stage Pipeline and Identifying Tebipenem’s Optimal Path to Value Creation Initiation of a Phase 2 Trial of SPR720 in Nontuberculous...
Spero Therapeutics to Present at Upcoming Investor Conferences
May 11, 2022 08:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results on Monday, May 16, 2022
May 09, 2022 08:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Monday, May 16, 2022, at 4:30...
Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline
May 03, 2022 07:05 ET
|
Spero Therapeutics, Inc.
Announces Immediate Cessation of Tebipenem HBr Commercialization Initiatives; Company to Shift Focus to Advancement of SPR720 and SPR206 Spero to Explore Strategic Partnerships and Other...
Spero Therapeutics to Present Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases
April 21, 2022 08:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced two oral presentations and four poster presentations at the 32nd European Congress of...
Spero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data Published in The New England Journal of Medicine
April 06, 2022 17:31 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced publication in The New England Journal of Medicine (NEJM) of the results from the Phase 3...